Detalles de la búsqueda
1.
Immunological impact of cell death signaling driven by radiation on the tumor microenvironment.
Nat Immunol
; 21(2): 120-134, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31873291
2.
Cell-type-specific tumour sensitivity identified with a bromodomain targeting PROTAC in adenoid cystic carcinoma.
J Pathol
; 262(1): 37-49, 2024 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37792636
3.
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial.
Lancet Oncol
; 25(5): 572-587, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38561010
4.
Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141.
Oncologist
; 27(2): e194-e198, 2022 03 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35641218
5.
Triggering anti-GBM immune response with EGFR-mediated photoimmunotherapy.
BMC Med
; 20(1): 16, 2022 01 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-35057796
6.
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.
Lancet
; 393(10167): 156-167, 2019 01 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30509740
7.
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Lancet
; 394(10212): 1915-1928, 2019 11 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-31679945
8.
The immunological consequences of radiation-induced DNA damage.
J Pathol
; 247(5): 606-614, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30632153
9.
Potentiating Oncolytic Virus-Induced Immune-Mediated Tumor Cell Killing Using Histone Deacetylase Inhibition.
Mol Ther
; 27(6): 1139-1152, 2019 06 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-31053413
10.
Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial.
Cancer
; 125(18): 3208-3218, 2019 09 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-31246283
11.
Near-infrared photoimmunotherapy targeting EGFR-Shedding new light on glioblastoma treatment.
Int J Cancer
; 142(11): 2363-2374, 2018 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29313975
12.
CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer.
Oncologist
; 23(9): 1079-1082, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-29866947
13.
Changes in multimodality functional imaging parameters early during chemoradiation predict treatment response in patients with locally advanced head and neck cancer.
Eur J Nucl Med Mol Imaging
; 45(5): 759-767, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29164301
14.
Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
Lancet Oncol
; 18(8): 1104-1115, 2017 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-28651929
15.
Correction: Triggering anti-GBM immune response with EGFR-mediated photoimmunotherapy.
BMC Med
; 20(1): 179, 2022 May 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35505318
16.
Letter to the Editor Regarding "An Evidence-Based Staging System for Mucosal Melanoma: A Proposal".
Ann Surg Oncol
; 29(Suppl 3): 625, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36175709
17.
HSP90 inhibition sensitizes head and neck cancer to platin-based chemoradiotherapy by modulation of the DNA damage response resulting in chromosomal fragmentation.
BMC Cancer
; 17(1): 86, 2017 01 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-28143445
18.
Isolated limb perfusion with biochemotherapy and oncolytic virotherapy combines with radiotherapy and surgery to overcome treatment resistance in an animal model of extremity soft tissue sarcoma.
Int J Cancer
; 139(6): 1414-22, 2016 09 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-27116656
19.
Further clinical interpretation and implications of KEYNOTE-048 findings - Authors' reply.
Lancet
; 396(10248): 379-380, 2020 08 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32771104
20.
HOX transcription factors are potential targets and markers in malignant mesothelioma.
BMC Cancer
; 16: 85, 2016 Feb 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-26867567